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ABSTRACT
Objective: The purpose of this study was to investigate the prognostic value of lymph node 
ratio (LNR) in patients with stage III ovarian high-grade serous carcinoma (HGSC).
Methods: A multicenter, retrospective department database review was performed to 
identify patients with ovarian HGSC at 6 gynecologic oncology centers in Turkey. A total 
of 229 node-positive women with stage III ovarian HGSC who had undergone maximal or 
optimal cytoreductive surgery plus systematic lymphadenectomy followed by paclitaxel plus 
carboplatin combination chemotherapy were included. LNR, defined as the percentage of 
positive lymph nodes (LNs) to total nodes recovered, was stratified into 3 groups: LNR1 
(<10%), LNR2 (10%≤LNR<50%), and LNR3 (≥50%). Kaplan-Meier method was used to 
generate survival data. Factors predictive of outcome were analyzed using Cox proportional 
hazards models.
Results: Thirty-one women (13.6%) were classified as stage IIIA1, 15 (6.6%) as stage IIIB, and 
183 (79.9%) as stage IIIC. The median age at diagnosis was 56 (range, 18–87), and the median 
duration of follow-up was 36 months (range, 1–120 months). For the entire cohort, the 5-year 
overall survival (OS) was 52.8%. An increased LNR was associated with a decrease in 5-year 
OS from 65.1% for LNR1, 42.5% for LNR2, and 25.6% for LNR3, respectively (p<0.001). In 
multivariate analysis, women with LNR≥0.50 were 2.7 times more likely to die of their tumors 
(hazard ratio [HR]=2.7; 95% confidence interval [CI]=1.42–5.18; p<0.001).
Conclusion: LNR seems to be an independent prognostic factor for decreased OS in stage III 
ovarian HGSC patients.
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INTRODUCTION
Lymph node ratio (LNR) is defined as the number of metastatic lymph nodes (LNs) divided 
by the total number of LNs removed. LNR has been shown to be useful in identifying 
prognostic subgroups within colorectal [1], gastric [2], breast [3], esophageal [4] cancer 
patients. Several recent studies have focused on the clinical relevance of LNR in assessing 
prognosis of gynecologic malignancies but the information of its prognostic significance is 
scant [5-9].
Today, it is well-known that epithelial ovarian cancer (EOC) is not a single disease but 
rather a group of diseases — each with different morphology and biologic behavior [10]. 
At least 5 main types are currently distinguished: high-grade serous carcinoma (HGSC; 
70%), endometrioid carcinoma (10%), clear-cell carcinoma (10%), mucinous carcinoma 
(3%), and low-grade serous carcinoma (LGSC; <5%) [11]. Patients with EOC of different 
histological types and grades have different probabilities of LN metastasis [12-15]. Especially 
patients with ovarian HGSC have an increased risk for LN metastasis [12-15]. Thus, distinct 
histopathological features might characterize tumor cells metastasizing through the 
lymphatic route.
However, previous studies which have investigated the prognostic impact of LNR in EOC 
analyzed all histologic types and grades simultaneously [7-9]. The number of prior studies 
investigating the prognostic significance of LNR in EOC seems to be limited [7-9], and 
the prognostic impact of LNR in ovarian HGSC has not been clearly delineated. Under 
the current perspective that the different histological subtypes in ovarian cancer probably 
represent different disease entities [16], we conducted this multicenter retrospective analysis 
aiming at a better understanding of the prognostic impact of LNR in ovarian HGSC.
The purpose of this study was to investigate the prognostic value of LNR in patients with 
stage III ovarian HGSC who have undergone systematic LN dissection during primary upfront 
surgery resulting in maximal or optimal cytoreduction.
MATERIALS AND METHODS
1. Study design and eligibility
After Institutional Review Board approval of Zekai Tahir Burak Women's Health Training 
and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey 
(IRB approval number: 15, date: May 29, 2017), patients with EOC who had been treated 
with upfront surgery between January 2007 and December 2016 at 6 gynecologic oncology 
centers from Turkey were retrospectively reviewed. All patients gave informed consent for the 
surgical procedure and research use of their medical information at admission.
The study population included women who had high-grade serous EOC with 
histopathologically proven International Federation of Gynecology and Obstetrics (FIGO) 
stage III [17] disease. Women were included if they had undergone primary surgical 
treatment including total hysterectomy plus bilateral salpingo-oopherectomy, with bilateral 
pelvic and para-aortic lymphadenectomy and other surgical procedures resulting in maximal 
or optimal debulking. Since this study focused only on women having high-grade serous 
EOC; women with LGSC, those with non-serous EOC (i.e., endometrioid, clear-cell, 
2/10https://ejgo.org https://doi.org/10.3802/jgo.2018.29.e12
Lymph node ratio and ovarian cancer
mucinous, and mixed subtypes) were excluded. Exclusion criteria also included absence 
of LN dissection, absence of metastatic LNs, patients with suboptimal cytoreduction, and 
women receiving non-systematic lymphadenectomy. We also excluded patients who received 
neoadjuvant chemotherapy, women with synchronous malignancies, women with stage IV 
disease, and those with incomplete medical records.
2. Clinical information
Patient data were extracted from 6 institutions with maintained EOC databases. With the 
eligible cases, the following information was abstracted from medical records: demographic 
characteristics, date and type of surgical procedure, presence or absence of ascites, the status 
of peritoneal cytology examination (negative or positive), size of the primary tumor, size of 
residual tumor after surgery, stage of disease, the date of diagnosis, length of follow-up, and 
survival. Tumor characteristics were abstracted from original pathology reports. Data were 
collected from centers with an online standardized form.
Data on the extent of surgery included number of total LNs removed, number of pelvic 
LNs removed, and number of para-aortic LNs removed and number of metastatic LNs. 
All operations were performed by gynecologic oncologists with intent to achieve optimal 
cytoreduction. Lymphadenectomy was performed after completion of other cytoreductive 
procedures.
All surgical specimens were examined and interpreted by gynecologic pathologists. Serous 
EOC was diagnosed based on the World Health Organization (WHO) classification [11] after 
examination of permanent sections. Architectural grading was defined by standard FIGO 
criteria. All tumors were staged according to the 2014 FIGO staging system [17]. In patients 
treated before 2014, stage was determined retrospectively on the basis of surgical and 
pathologic assessment.
The treatment policies were decided by the attending physician or by the multidisciplinary 
tumor board at each participating institution. Adjuvant chemotherapy was administered to 
all patients. The standard primary chemotherapy regimen included paclitaxel (Taxol®; Bristol-
Myers Squibb Company, Princeton, NJ, USA) 175 mg/m2 plus carboplatin (Paraplatin®; Bristol-
Myers Squibb Company) dosed at an area under curve of 5 or 6 every 21 days for 6 cycles.
Patients returned for follow-up evaluation every 3 months for the first 2 years, every 6 months 
for the next 3 years, and annually thereafter. Computed tomography or magnetic resonance 
imaging was performed annually. Survival data were last calculated on 31 December 2016. 
The survival status of the patients was determined as alive or dead at the time of the last 
follow-up. For all study subjects with a recorded death, this was confirmed by performing a 
social security death index search.
3. Definitions
LNR, defined as the percentage of positive LNs to total nodes recovered, was stratified into 3 
groups: LNR1 (<10%), LNR2 (10%≤LNR<50%), and LNR3 (≥50%) as described by Mahdi  
et al. [7].
Maximal debulking was defined as no gross residual disease after primary cytoreductive 
surgery. Optimal cytoreduction was defined as less than or equal to 1 cm maximal diameter 
of the largest residual tumor nodule at the completion of the primary operation whereas 
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suboptimal debulking was defined as >1 cm of residual disease after primary cytoreductive 
surgery. Systematic lymphadenectomy was defined as the removal of at least 20 pelvic and 10 
para-aortic LNs [18].
Overall survival (OS) was calculated as the time period between primary cytoreductive 
surgery to the date of death or the last follow-up. Surviving patients were censored at their 
last known follow-up.
4. Statistical analysis
Statistical analyses were performed using the statistical software package SPSS version 23.0 
(SPSS Inc., Chicago, IL, USA). The data were expressed as median and range for continuous 
variables. The continuous variables such as age and tumor size have been divided into 
categories according to the median values. Binary variables were reported as counts and 
percentages.
Survival curves were generated using the Kaplan-Meier method, and the differences between 
survival curves were calculated using the log-rank test. In order to evaluate the prognostic 
factors for OS, a univariate Cox-regression model was used. Any p-value of less than 0.05 in 
the univariate analysis was subjected to multivariate analysis. A p-value <0.05 was considered 
to indicate statistical significance.
RESULTS
A total of 229 women met the inclusion criteria; 31 (13.6%) were classified as stage IIIA1, 
15 (6.6%) as stage IIIB, and 183 (79.9%) as stage IIIC. The median age at diagnosis was 56 
(range, 18–87) and the median duration of follow-up was 36 months (range, 1–120 months). 
Table 1 demonstrates the clinical and pathological characteristics of node-positive women 
with stage III ovarian HGSC.
The median number of total LNs harvested was 63 (range, 32–132). The median number of 
pelvic and para-aortic LNs removed was 36 (range, 20–79), and 23 (range, 10–85), respectively. 
There were 187 patients with pelvic LN involvement (81.6%), and 194 patients with para-aortic 
LN involvement (84.7%). Isolated pelvic LN metastasis was detected in 35 women (15.2%). 
There were 42 patients with isolated para-aortic LN metastasis (18.3%). One hundred fifty-
two patients (66.3%) had pelvic and para-aortic LN metastases at the same time. The median 
number of metastatic pelvic and para-aortic LNs was 2 (range, 0–50) and 3 (range, 0–46), 
respectively. Finally, the median number of total metastatic LNs was 5 (range, 1–89).
For the entire cohort, the median LNR was 8.4% (range, 0.9%–90.4%). There were 120 
(52.4%) women with LNR1, 81(35.4%) women with LNR2, and 28 (12.2%) with LNR3. The 
median LNR was 6.9% (range, 1.3%–7.6%) for stage IIIA1, 5.7% (range, 1.7%–5.8%) for stage 
IIIB, and 9.7% (range, 0.9%–90.4%) for stage IIIC. The 5-year OS was 52.8% for the entire 
cohort. This figure was found to be 75.5% for stage IIIA1 disease, 48.1% for stage IIIB, and 
49.9% for stage IIIC (p<0.049) (Fig. 1).
An increased LNR was associated with a decrease in 5-year OS from 65.1% for LNR1, 42.5% 
for LNR2, and 25.6% for LNR3, respectively (p<0.001; Fig. 2). Further prognostic factors 
in univariate analysis were stage, and omental involvement (Table 2). In multivariate Cox 
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regression analysis; LNR was an independent prognostic factor for OS after adjusting for 
other clinically relevant factors in univariate analysis (Table 2). Women with LNR2 were 2.3 
times more likely to die of their tumors (hazard ratio [HR]=2.3; 95% confidence interval 
[CI]=1.46–3.8; p=0.003) whereas patients with LNR3 had a worse prognosis (HR=2.7; 95% 
CI=1.42–5.18; p<0.001). At the time of reporting, of 229 node-positive women with ovarian 
HGSC, 143 (62.4%) were alive and 86 (37.6%) were dead.
DISCUSSION
The key findings of the current study indicate that LNR seems to be an independent 
prognostic factor for OS in stage III ovarian HGSC. Women with LNR2 were 2.3 times more 
likely to die of their tumors (HR=2.3; 95% CI=1.46–3.8; p=0.003) whereas patients with LNR3 
had a worse prognosis (HR=2.7; 95% CI=1.42–5.18; p<0.001).
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Table 1. Baseline characteristics of the patients
Characteristic Values
Age (yr) 56 (18–87)
≤56 119 (52)
>56 10 (48)
Menopausal status
Premenopausal 66 (28.8)
Postmenopausal 163 (71.2)
Grade
2 51 (22.3)
3 178 (77.7)
Tumor size (cm) 12 (4–40)
<12 133 (58.1)
≥12 96 (41.9)
Ascites
Present 171 (74.7)
Absent 58 (25.3)
Peritoneal cytology
Positive 186 (81.2)
Negative 43 (18.8)
LNs removed 63 (32–132)
Pelvic LNs 36 (20–79)
Para-aortic LNs 23 (10–85)
Positive LNs 5 (1–89)
Pelvic LNs 2 (0–50)
Para-aortic LNs 3 (0–46)
LNR (%) 8.4 (0.9–90.4)
<10 120 (52.4)
10–49 81 (35.4)
≥50 28 (12.5)
FIGO stage
IIIA1 31 (13.6)
IIIB 15 (6.6)
IIIC 183 (79.9)
Cytoreduction
Maximal 144 (62.9)
Optimal 85 (37.1)
Status
Alive 143 (62.4)
Dead 86 (37.6)
Values are presented as number (median) or number (%).
FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; LNR, lymph node ratio.
However, we should underline some limitations of the current study. First, our study is 
retrospective in nature and thus confounding factors might have been missed. Second, 
though the differences in survival among groups were statistically significant, causation 
cannot be proven based on our data. Third, our study was also restricted by a lack of central 
pathology review. Despite above limitations, our findings provide additional information to 
the limited body of knowledge on this topic.
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Time (mo)
0.6
0.4
0.2
0 20 40 60 80 100 120
O
S
0.8
1.0
p<0.049
IIIA1 vs. IIIB, p=0.027
IIIA1 vs. IIIC, p=0.015
IIIB vs. IIIC, p=0.968
IIIB
IIIA1
Stage
IIIC
IIIB-censored
IIIA1-censored
IIIC-censored
Fig. 1. OS analysis of patients with regard to stage of disease. Number of patients was 31 as stage IIIA1, 15 as stage 
IIIB, and 183 as stage IIIC. 
OS, overall survival.
Time (mo)
0.6
0.4
0.2
0 20 40 60 80 100 120
O
S
0.8
1.0
p<0.001
LNR1 vs. LNR2, p=0.001
LNR1 vs. LNR3, p<0.001
LNR2 vs. LNR3, p=0.605
LNR2
LNR1
LNR
LNR3
LNR2-censored
LNR1-censored
LNR3-censored
Fig. 2. OS analyses with regard to LNR. Number of patients were 120, 81, and 28 for LNR1 (<10%), LNR2 
(10%≤LNR<50%), and LNR3 (≥50%). 
LNR, lymph node ratio; OS, overall survival.
There is no numerical significance of the harvested LNs and the positive LNs in the FIGO 
staging system. The number of harvested LNs is dependent on the surgeon, the pathologist, 
and the patient (i.e., age, and performance status) [19,20]. Zhou et al. [9] suggested that LNR 
may reduce the potential bias due to variations of surgeons and pathologists which may affect 
accurate assessment of LN status. However, Ataseven et al. [8] reported that the potential 
value of LNR may be based on its composition of both tumor biology and extent of surgical 
effort and the authors emphasized that the latter may be seen as one of the theoretical 
weaknesses of this parameter.
Three retrospective studies have reported that high LNR is independently associated with 
decreased OS in patients with advanced EOC [7-9]. Mahdi et al. [7] used the Surveillance, 
Epidemiology, and End Results (SEER) database and analyzed the prognostic significance 
of LNR for 6,310 patients with FIGO stages III and IV EOC who underwent surgery between 
1988 and 2006. Patients who had positive LNs were divided into 3 groups according to 
LNR; LNR1 (<10%), LNR2 (10%–50%), and LNR3 (>50%). They found out that LNR was 
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Table 2. Univariate and multivariate analyses of all patients for OS
Characteristic OS* Univariate analyses Multivariate analyses
HR CI 95% p HR CI 95% p
Age (yr) 1.12 0.734–1.719 0.590
≤56 49.3
>56 56.2
Menopausal status 1.04 0.654–1.664 0.850
Premenopausal 46.3
Postmenopausal 55.4
Grade 1.40 0.870–2.280 0.160
Grade 2 58.5
Grade 3 50.3
Tumor size (cm) 1.37 0.885–2.132 0.150
≤12 50.2
>12 56.3
Ascites 1.40 0.822–2.439 0.200
Yes 49.8
No 62.9
Malign cytology 1.15 0.649–2.052 0.600
Yes 51.4
No 58.9
Cytoreduction 1.27 0.828–1.957 0.260
Maximal 54.7
Optimal 51.0
Omental involvement 2.5 1.210–5.189 0.010 1.9 0.700–5.150 0.200
Yes 48.8
No 71.4
FIGO stage
IIIA1 75.5
IIIB 48.1
IIIC 49.9
IIIA1 vs. IIIB 3.2 1.121–10.750 0.027 1.7 0.380–8.280 0.46
IIIA1 vs. IIIC 3.2 1.194–8.944 0.015 1.7 0.450–7.020 0.40
LNR
LNR1 (<10%) 65.1
LNR2 (10%≤LNR<50%) 42.5
LNR3 (≥50%) 25.6
LNR1 vs. LNR2 2.2 1.423–3.673 0.001 2.3 1.460–3.803 0.003
LNR1 vs. LNR3 2.7 1.425–5.140 <0.001 2.7 1.420–5.188 <0.001
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; LNR, lymph node ratio; OS, overall survival.
*Five-year OS (%).
an independent prognostic factor for survival, especially in patients with no macroscopic 
peritoneal disease [7]. Based on the percentage of metastatic LNs, an increased ratio of 
metastatic LNs was reported to be associated with a decrease in 5-year survival from 51.5% 
for LNR1, 38.1% for LNR2, and 27.0% for LNR3, respectively (p<0.001) [7]. These figures 
were found to be 65.1%, 42.5%, and 25.6%, respectively (p<0.001) in our study; comparable 
to those of Mahdi et al. [7].
Although Mahdi et al. [7] reported that the prognostic significance of LNR persisted 
irrespective of the extent of LN dissection; the extent of lymphadenectomy seems to be the 
major limitation of their study. In their cohort, 58.0% and 21.1% of patients had ≤10 and 
11–20 LNs removed, respectively. It should be emphasized that just a small amount of patients 
(20.8%) had comprehensive lymphadenectomy with >20 LNs removed in their study [7]. 
Additionally, approximately 35.2% of their cohort exhibited non-serous histology [7].
Zhou et al. [9] also used the SEER database and examined 5,926 patients with stage IIIC 
EOC. The authors reported LNR to be a good prognostic marker for stage IIIC EOC patients 
after stratification by the number of resected LNs, tumor histology and tumor grade. They 
used ROC analysis and determined 0.42 as the optimal cut-off point for LNR [9]. Zhou et 
al. [9] emphasized that LNR had a more significant impact on survival in EOC than the 
number of removed LNs and the number of positive LNs. However, SEER database lacks 
several important variables such as extent and outcome of initial surgery including the size of 
residual disease, type of adjuvant chemotherapy, and recurrence. Additionally, 18.2% of their 
cohort exhibited non-serous histology [7].
Ataseven et al. [8] reported on 809 patients with FIGO stage I–IV EOC of whom 398 had 
node-positive disease. Their results indicated that LNR provided additional information 
compared to LN status alone. The authors emphasized that patients with LN metastasis 
presented with a median OS of 44 months. Patients with a LNR≤0.25 presented with a 
median OS of 52 months compared to a median OS of 30 months for patients having a 
LNR>0.25 [8]. Ataseven et al. [8] concluded that LNR could be an easily assessable parameter 
in operated EOC, which allows a favorable and further prognostic discrimination of node-
positive disease. It should be emphasized that 27.2% of their study population exhibited 
non-serous histology.
Compared to previous studies [7-9], our cohort seems to be more homogenous with all 
patients having high-grade serous histotype, and all patients having undergone maximal or 
optimal cytoreduction as well as systematic LN dissection. Additionally, all patients were 
treated with the standard paclitaxel/carboplatin regimen postoperatively. These factors seem 
to reduce the possibility of confounding, and enhance the reliability of the prognostic effects 
those have been estimated.
Few previous studies have investigated the role of LNR in EOC, so there is no standard LNR 
cut-off point for comparisons of groups with lower and higher LNRs [9]. Instead of reporting 
a new cut-off value for LNR, we preferred to stratify our cohort by the LNR cut-offs described 
by Mahdi et al. [7] in order to make a comparison. In addition to this, we defined systematic 
lymphadenectomy as the removal of at least 20 pelvic and 10 para-aortic LNs as described in 
the lymphadenectomy in ovarian neoplasms (LION) study [18]. Although Harter et al. [18] 
have recently reported that systematic pelvic and para-aortic lymphadenectomy in patients 
with advanced ovarian cancer with both intra-abdominal complete resection and clinically 
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negative LNs improve neither overall nor progression-free survival despite detecting sub-
clinical retroperitoneal LN metastases in 56% of their patients, our data indicated that LNR 
seems to be an independent prognostic factor for decreased OS in node-positive stage III 
ovarian HGSC.
To the best of our knowledge, this is the first study that investigated the prognostic impact 
of LNR in stage III high-grade serous EOC. The strengths of the current study lie in its 
multicenter nature with a large number of node-positive patients with stage III ovarian 
HGSC. Our study has the advantage that its time period encompasses the last 10 years, 
during which all included patients were treated with standard paclitaxel/carboplatin regimen. 
Additionally, all of the patients in the current study underwent systematic LN dissection.
We conclude that LNR seems to be an independent prognostic factor for decreased OS in 
stage III ovarian HGSC patients. However, our findings may be confirmed or denied if the 
prognostic impact of LNR is investigated in a subgroup analysis of node-positive stage III 
ovarian HGSC patients included in the LION study [18].
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